A potential COVID-19 vaccine being developed by American pharma giant Pfizer and Germany-headquartered BioNTech is 90% effective, early data from a phase III trial suggests.
The phase III trial of Pfizer and BioNTech’s COVID-19 vaccine candidate – named BNT162b2 – involved 43,538 individuals, who received two doses of the vaccine or a placebo.
In an announcement released today, Pfizer and BioNTech said that their vaccine achieved an efficacy rate of over 90% seven days after receiving the second dose.
Within the trial, 94 participants developed the novel coronavirus, SARS-CoV-2, which causes COVID-19. The trial is continuing to enrol participants and is set to reach the final analysis when a total of 164 COVID-19 cases have occurred.
The companies added that they are accumulating safety data and currently estimate that a median of two months of safety data following the second dose of the vaccine will be ready by the third week of November.
Read more: http://www.pharmatimes.com/news/breaking_news_early_data_indicates_pfizerbiontechs_covid-19_vaccine_is_90_effective_1356395